An observational study in Hypertension, Morality and Death, sponsored by DejthidaNathaphong. Active, not recruiting at 1 site in Thailand. Open to participants aged 1 Minute to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by DejthidaNathaphong · Observational
This review focuses on the assumption of mortality outcome of participants remaining label hypertension care is adequately managed when pressure targets are met with both qualitative and quantitaive method.
For systematically review and synthesize the literature on main 2 questions
For Individual Participant Data Meta-analysis will be attracted from final analysis articles from the framework of data selection process only, the effect measurement and multi-variable model meta-analysis will be performed.
Sub-group analysis effect measurement following;
916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
This study's planned enrollment of 2,547 is above the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →DejthidaNathaphong is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Compared within Pre-Eclampsia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Studies including patients (any age or sex) with:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Human birth in all sex chromosomes.
Study reports evidence of living with owned systemic/arterial hypertension by one of definition following;
Study design: any type of studies and have a doi number.
Non human/human-specimen studies.
Mortality outcomes or casue which mainly suspected from hypertension
All-cause vascular mortality
Cardiovascular mortality (Cardiac-related death in controlled hypertension patients), cerebrovascular death(Stroke-related fatal outcomes in BP-controlled patients), renal occlusion/rupture/failure causing death (Mortality from renal failure in treated, controlled hypertensives), life-threatening vascular rupture, Major Adverse Cardiovascular Death or
Time frame: Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years
Sudden death
Death suddenly with autopsy or complete CPR during collapse of cardiac or respiratory or brain arrested
Time frame: Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years
End-organ failure leading to death
Vascular abnormality causing failure of organ leading death with evidence by imaging, laboratory investigation or autopsy
Time frame: 90 days outcomes after participant recruitment (death/alive)
ICU death
Systemic arterial hypertension is the main reason for admission at critical care unit report death
Time frame: 90 days outcomes start with day 1 admit at ICU (death/alive)
Maternal associated hypertension death
Mortality outcomes of hypertension during pregnancy both from gynecologic organ failure or systemic organ failure
Time frame: During pregnancy period from GA 1 week to delivery (pre-term, term-post-term) to 6 week follow up postpartum
Hypertension associated death in the young
Mortality outcomes that clear defined high blood pressure of that age and declared mortality cause during or after any type of treatment
Time frame: Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 18 years of ages of participant
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The study already registered from PROSPERO number CRD420251072526
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: TIMELINE OF THE REVIEW Date of first submission to PROSPERO 01 July 2025 Review timeline Start date: 14 June 2025. End date: 31 December 2026. Date of registration in PROSPERO 01 July 2025
Access criteria: Public registered
Data sharing details ↗ · www.crd.york.ac.uk
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DejthidaNathaphong